Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Regulatory News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of Major Holdings

5 Mar 2019 07:00

RNS Number : 8084R
ReNeuron Group plc
05 March 2019
 

TR-1: Standard form for notification of major holdings

 

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

ReNeuron Group PLC

LEI: 2138003TU12CQ5TZO137

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Details of person subject to the notification obligation

Name

Invesco Ltd.

City and country of registered office (if applicable)

1555 Peachtree Street NE, Suite 1800,

Atlanta, GA 30309 United States

4. Full name of shareholder(s) (if different from 3.)

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached:

01-03-2019

6. Date on which issuer notified (DD/MM/YYYY):

04-03-2019

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

9.89%

0

9.89%

31,646,186

Position of previous notification (if

applicable)

11.91%

0

11.91%

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

 

GB00BF5G6K95

Number of voting rights

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

 

 

3,132,955

 

9.89%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

3,132,955

9.89%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdate

Exercise/Conversion Period

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdat

Exercise/Conversion Period 

Physical or cash

settlement

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Invesco Asset

Management Ltd.

9.89%

0

9.89%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

Invesco (UK) Ltd.

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

 

11. Additional information

 

     

 

Place of completion

Henley-on-Thames

Date of completion

04-03-2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUGUUCWUPBGBC
Date   Source Headline
6th Sep 201711:15 amRNSResult of AGM
6th Sep 20177:00 amRNSAGM Trading Update
1st Sep 20177:00 amRNSNon-executive Director Appointment
1st Sep 20177:00 amRNSBlock Listing Review and TVR
7th Aug 20173:04 pmRNSPosting of Annual Report and Notice of AGM
4th Aug 20174:40 pmRNSSecond Price Monitoring Extn
4th Aug 20174:35 pmRNSPrice Monitoring Extension
25th Jul 20177:00 amRNSAppointment of joint broker
19th Jul 20177:00 amRNSBoard change
29th Jun 20177:00 amRNSPreliminary Results
19th Jun 20177:00 amRNSFDA approves cryopreserved hRPC formulation
8th Jun 20177:00 amRNSNotification of Preliminary Results
5th Jun 20177:00 amRNSPositive FDA feedback on proposed Phase III study
18th May 20177:00 amRNSPresents positive exosome data at major conference
11th May 20177:00 amRNSAwarded major UK cell therapy manufacturing grant
5th May 20177:00 amRNSPresents new exosome data at major conference
21st Apr 20177:01 amRNSUpdate on clinical strategy in stroke disability
21st Apr 20177:00 amRNSUpdate on progress in ophthalmology programmes
1st Mar 20177:00 amRNSBlock Listing Review and Total Voting Rights
15th Feb 20177:00 amRNSReNeuron featured in BBC documentary
7th Feb 201712:32 pmRNSDirector Share Purchase
14th Dec 201612:15 pmRNSDirector Share Purchase
5th Dec 20167:00 amRNSReports Positive Results in Phase II Stroke Trial
5th Dec 20167:00 amRNSInterim Results
14th Nov 20167:00 amRNSNotification of Interim Results
5th Oct 20162:30 pmRNSNotification of Major Interest in Shares
22nd Sep 20161:00 pmRNSBlock Listing Review and Total Voting Rights
6th Sep 201612:00 pmRNSResult of AGM
6th Sep 20167:00 amRNSAGM Trading Update
5th Aug 20164:35 pmRNSPosting of Annual Report and Notice of AGM
4th Aug 20167:00 amRNSStroke clinical data published in The Lancet
22nd Jul 20167:00 amRNSPublication of positive pre-clinical retinal data
20th Jul 20162:31 pmRNSDirectors' Interest in Shares and Share Options
7th Jul 20167:00 amRNSPreliminary Results
14th Jun 20167:00 amRNSNotification of Preliminary Results
13th Jun 20167:00 amRNSPatient recruitment completed in stroke trial
9th Jun 20167:01 amRNSPursues brain cancer with exosome platform
8th Jun 20167:00 amRNSRetinitis pigmentosa update & Notice of KOL event
31st May 201612:45 pmRNSChange of Adviser
15th Mar 20167:00 amRNSFirst Patient Treated in RP Clinical Trial
23rd Feb 20167:00 amRNSReNeuron Relocates to South Wales
17th Feb 20164:57 pmRNSDirector's Dealings
3rd Feb 201610:07 amRNSDirector Share Purchase
1st Feb 20167:00 amRNSNotice of Grant of Key US Patent
12th Jan 20167:00 amRNSPre-clinical data relating to exosome platform
11th Jan 20167:00 amRNSWins UK grant to advance its exosome platform
17th Dec 20157:00 amRNSReNeuron establishes Scientific Advisory Board
7th Dec 20157:00 amRNSInterim Results
4th Dec 20157:00 amRNSNon-executive Director appointment
12th Nov 20152:45 pmRNSNotification of Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.